Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC

Affiliations

¹ Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland; Immuno-oncology Service, Department of Oncology, Lausanne University Hospital, 1011 Lausanne, Switzerland.
² Radiation Oncology Service, Department of Oncology, Lausanne University Hospital, 1011 Lausanne, Switzerland.
³ Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland; Immuno-oncology Service, Department of Oncology, Lausanne University Hospital, 1011 Lausanne, Switzerland; Radiation Oncology Service, Department of Oncology, Lausanne University Hospital, 1011 Lausanne, Switzerland. Electronic address: Fernanda.Herrera@chuv.ch.

Comment

Maria Ochoa-de-Olza et al. Lancet Oncol. 2022 Apr.

. 2022 Apr;23(4):e157.

doi: 10.1016/S1470-2045(22)00154-1.

¹ Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland; Immuno-oncology Service, Department of Oncology, Lausanne University Hospital, 1011 Lausanne, Switzerland.
² Radiation Oncology Service, Department of Oncology, Lausanne University Hospital, 1011 Lausanne, Switzerland.
³ Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland; Immuno-oncology Service, Department of Oncology, Lausanne University Hospital, 1011 Lausanne, Switzerland; Radiation Oncology Service, Department of Oncology, Lausanne University Hospital, 1011 Lausanne, Switzerland. Electronic address: Fernanda.Herrera@chuv.ch.

No abstract available

Conflict of interest statement

We declare no competing interests.

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, Liu Y, Brennick RC, Gentzler RD, Lee C, Hubbard J, Arnold SM, Abbruzzese JL, Jabbour SK, Uboha NV, Stephans KL, Johnson JM, Park H, Villaruz LC, Sharon E, Streicher H, Ahmed MM, Lyon H, Cibuskis C, Lennon N, Jhaveri A, Yang L, Altreuter J, Gunasti L, Weirather JL, Mak RH, Awad MM, Rodig SJ, Chen HX, Wu CJ, Monjazeb AM, Hodi FS. Schoenfeld JD, et al. Lancet Oncol. 2022 Feb;23(2):279-291. doi: 10.1016/S1470-2045(21)00658-6. Epub 2022 Jan 13. Lancet Oncol. 2022. PMID: 35033226 Free PMC article. Clinical Trial.